{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:43:55Z","timestamp":1791377035978,"version":"4.3.2"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Anemia represents one of the most prevalent complications of chronic kidney disease (CKD). Investigation of the regulation of erythropoietin production led to the discovery of oxygen-sensing mechanisms, which are now being targeted therapeutically (hypoxia-inducible factor prolyl hydroxylase inhibitors, HIF-PHI). Roxadustat, a first-in-class of HIF-PHI, achieved its first approval in China in December 2018 for managing anemia in adult patients with CKD. Over the past 6\u00a0years, we have gained substantial real-world experience regarding its therapeutic application. Accordingly, accumulated evidence demonstrates that roxadustat is superior to placebo and non-inferior to current standard-of-care erythropoiesis-stimulating agents in correcting and maintaining hemoglobin concentration at target levels among patients with non-dialysis dependent CKD and incident and dialysis dependent CKD. However, given the pleiotropic effects of HIF activation, the pharmacologic activation of HIF in patients with anemia of CKD is also likely to have effects beyond erythropoiesis and iron metabolism. In this review, we synthesize clinical insights from these novel therapeutics and highlight some of the outstanding questions relevant to their clinical use. This study may provide theoretical framework and practical evidence for the clinical application of other HIF-PHIs.<\/jats:p>","DOI":"10.3389\/fphar.2025.1712869","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:47Z","timestamp":1767768707000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Roxadustat for renal anemia: current clinical experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Jialing","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD","volume":"6","author":"Akizawa","year":"","journal-title":"Kidney Int. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"","journal-title":"Ther. Apher. Dial."},{"key":"B3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1159\/000519043","article-title":"Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients","volume":"52","author":"Akizawa","year":"","journal-title":"Am. J. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ekir.2024.06.042","article-title":"Roxadustat: more than an erythropoietic agent?","volume":"10","author":"Angeletti","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"","journal-title":"Adv. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s12325-023-02433-0","article-title":"Safety of roxadustat versus erythropoiesis-stimulating agents in patients with anemia of non-dialysis-dependent or incident-to-dialysis chronic kidney disease: pooled analysis of four phase 3 studies","volume":"40","author":"Barratt","year":"2023","journal-title":"Adv. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/ndt\/gfad017","article-title":"Suppression of thyroid profile during roxadustat treatment in chronic kidney disease patients","volume":"38","author":"Cheng","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-Related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/CM9.0000000000003672","article-title":"Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: the ROXSTAR registry","volume":"138","author":"Du","year":"2025","journal-title":"Chin. Med. J. Engl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.3390\/jcm12134217","article-title":"Iron parameters in patients treated with roxadustat for anemia of chronic kidney disease","volume":"12","author":"Ganz","year":"2023","journal-title":"J. Clin. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jfutfo.2023.07.005","article-title":"Protective effects and microarray-based mechanism of sea cucumber hydrolysates against high-glucose induced nephrotoxicity in mouse glomerulus mesangial cells","volume":"4","author":"Geng","year":"2024","journal-title":"J. Future Foods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ajh.26865","article-title":"Open-label, phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies","volume":"98","author":"Glaspy","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13318-020-00658-w","article-title":"Effect of kidney function and dialysis on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"46","author":"Groenendaal-van de Meent","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ndt\/gfab050","article-title":"Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia","volume":"36","author":"Guedes","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in nondialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"","journal-title":"J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int. Suppl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial","volume":"121","author":"Hou","year":"","journal-title":"J. Formos. Med. Assoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.jfma.2022.06.008","article-title":"Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a meta-analysis","volume":"121","author":"Hou","year":"","journal-title":"J. Formos. Med. Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5414\/CN111433","article-title":"The efficacy and safety of low-dose roxadustat in combination with recombinant human erythropoietin for treating hemodialysis patients with moderate anemia: a retrospective cohort study","volume":"103","author":"Huang","year":"2025","journal-title":"Clin. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"B34","article-title":"KDIGO 2025 clinical practice guideline for the anemia in chronic kidney disease (CKD)","year":"2025","journal-title":"Kidney Int. Suppl"},{"key":"B35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2413176","DOI":"10.1155\/2022\/2413176","article-title":"Efficacy and safety of roxadustat in patients with chronic kidney disease: an updated meta-analysis of randomized controlled trials including 6,518 patients","volume":"2022","author":"Lei","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12630","DOI":"10.1096\/fj.201901087RR","article-title":"The profibrotic effects of MK-8617 on tubulointerstitial fibrosis mediated by the KLF5 regulating pathway","volume":"33","author":"Li","year":"2019","journal-title":"FASEB J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis. (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1038\/s41401-021-00617-4","article-title":"FIH-1-modulated HIF-1alpha C-TAD promotes acute kidney injury to chronic kidney disease progression via regulating KLF5 signaling","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"B40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1089\/ars.2021.0271","article-title":"Disturbance of hypoxia response and its implications in kidney diseases","volume":"37","author":"Li","year":"2022","journal-title":"Antioxid. Redox Signal"},{"key":"B41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000542699","article-title":"Effects of roxadustat on thyroid profiles in patients and animals with chronic kidney disease","volume":"56","author":"Li","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"724456","DOI":"10.3389\/fmed.2021.724456","article-title":"Safety and efficacy of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis and trial sequential analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/JCO.23.02742","article-title":"Efficacy and safety of roxadustat for anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, open-label, active-controlled phase III study","volume":"43","author":"Lu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","article-title":"Hypoxia signaling in human health and diseases: implications and prospects for therapeutics","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12882-024-03474-5","article-title":"Impact of C-reactive protein on the effect of roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials","volume":"25","author":"Luo","year":"2024","journal-title":"BMC Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ajh.27410","article-title":"Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial","volume":"99","author":"Mittelman","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1242\/jcs.106682","article-title":"Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression","volume":"125","author":"Mylonis","year":"2012","journal-title":"J. Cell Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.34067\/KID.0001442022","article-title":"Changes in iron availability with roxadustat in nondialysis- and dialysis-dependent patients with anemia of CKD","volume":"3","author":"Pergola","year":"2022","journal-title":"Kidney360"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jcph.1648","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: a placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients","volume":"60","author":"Provenzano","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kisu.2020.12.006","article-title":"Treatment of anemia in difficult-to-manage patients with chronic kidney disease","volume":"11","author":"Raichoudhury","year":"2021","journal-title":"Kidney Int. Suppl. (2011)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Sch\u00f6del","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3000605231204475","DOI":"10.1177\/03000605231204475","article-title":"Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients","volume":"51","author":"Song","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the european renal best practice board of the european renal association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"key":"B59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bcp.15023","article-title":"Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia","volume":"88","author":"Takada","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2169\/internalmedicine.3773-24","article-title":"Roxadustat for treating anemia in patients with advanced chronic kidney disease not undergoing dialysis: a retrospective study","volume":"64","author":"Tamaki","year":"2025","journal-title":"Intern Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"658079","DOI":"10.3389\/fphar.2021.658079","article-title":"Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat","volume":"12","author":"Tang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2313864","DOI":"10.1080\/0886022X.2024.2313864","article-title":"Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis","volume":"46","author":"Tian","year":"2024","journal-title":"Ren. Fail"},{"key":"B63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000538372","article-title":"Roxadustat on renal anemia with macroinflammation: a retrospective cohort study","volume":"10","author":"Tu","year":"2024","journal-title":"Kidney Dis. (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12964-025-02175-2","article-title":"The roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage","volume":"23","author":"Wang","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"B65","first-page":"5120","article-title":"Safety and effectiveness of recombinant human erythropoietin coupled with different doses of roxadustat for treatment of renal anemia in patients on maintenance hemodialysis","volume":"15","author":"Wei","year":"2023","journal-title":"Am. J. Transl. Res."},{"key":"B66","first-page":"1463","article-title":"Work group on guidelines for renal anemia of nephrologists branch of Chinese medical doctor association. Clinical practice guidelines for diagnosis and treatment of renal anemia in China","volume":"101","year":"2021","journal-title":"Chin. Med. J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12325-023-02741-5","article-title":"Roxadustat and oral iron absorption in Chinese patients with anemia of chronic kidney disease: a randomized, open-label, phase 4 study (ALTAI)","volume":"41","author":"Wu","year":"2024","journal-title":"Adv. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ekir.2021.12.025","article-title":"Randomized study on the efficacy of standard versus low roxadustat dose for anemia in patients on peritoneal dialysis","volume":"7","author":"Yang","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao","year":"2019","journal-title":"iScience"},{"key":"B70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrol. Carlt."},{"key":"B71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5414\/CN111144","article-title":"Comparative analysis of roxadustat efficacy between maintenance hemodialysis and peritoneal dialysis patients","volume":"101","author":"Zhang","year":"2024","journal-title":"Clin. Nephrol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1159\/000548711","article-title":"Comparative effectiveness and safety of roxadustat versus erythropoiesis-stimulating agents in patients receiving maintenance hemodialysis: a real-world cohort study","volume":"11","author":"Zhang","year":"2025","journal-title":"Kidney Dis. (Basel)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1161\/atvbaha.121.316495","article-title":"Roxadustat does not affect platelet production, activation, and thrombosis formation","volume":"41","author":"Zhao","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/ckj\/sfad080","article-title":"Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study","volume":"16","author":"Zhao","year":"2023","journal-title":"Clin. Kidney J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2195011","DOI":"10.1080\/0886022X.2023.2195011","article-title":"The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Zhou","year":"2023","journal-title":"Ren. Fail"},{"key":"B76","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/jbmr\/zjaf032","article-title":"Roxadustat increases markers of calcification in patients with end-stage kidney disease: prospective cohort study","volume":"40","author":"Zhu","year":"2025","journal-title":"J. Bone Min. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1712869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:49Z","timestamp":1767768709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1712869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":76,"alternative-id":["10.3389\/fphar.2025.1712869"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1712869","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1712869"}}